Emergent BioSolutions Inc. filed a Current Report on Form 8-K on September 14, 2026, announcing that President and Chief Executive Officer Joseph C. Papa will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation, furnished as Exhibit 99.1 to the filing, is incorporated by reference into the report.
The filing details the company's current business strategy and product portfolio, which includes a diverse range of medical countermeasures (MCMs) and naloxone products. The company highlights its capabilities in biodefense and public health protection, noting recent regulatory approvals for ACAM2000 by the Saudi Food and Drug Authority and an expansion of its indication to include Mpox by the Singapore Health Sciences Authority.
The presentation outlines a multi-year transformation plan aimed at improving operating performance and balance sheet strength. Key restructuring initiatives mentioned include a reorganization expected to generate annualized savings of approximately $40 million. Specific actions planned to achieve these savings include the closure of two laboratories in Maryland, the sale of an unutilized office building for approximately $6 million, and the exit of a Maryland warehouse lease. Additionally, the company plans to reduce its workforce by 90 roles and create a new Growth organization to integrate R&D, Business Development, and Strategy.
The filing also addresses the competitive landscape of the naloxone market, noting that since the OTC FDA approval in 2023, the company has faced intensified competition, including new 4 mg OTC and 10 mg prescription entrants, as well as generic options. The company states that these market dynamics have led to more aggressive pricing and eroded sector margins.
The document contains forward-looking statements regarding future performance, including the availability of U.S. government funding for contracts, the ability to meet quality commitments, the success of commercialization efforts, and the company's ability to comply with financial covenants under its term loan and revolving credit facilities.
